"Klinische Studien sind der Schlüssel zu neuen Erkenntnissen in der Diagnostik und Therapie von Erkrankungen. Wir sind stolz, in der Schweiz dazu beizutragen."

Klaudia Georgi, Director Clinical Research MSD Switzerland & Austria

15

In der Schweiz zugelassene First-in-Class-Medikamente seit 2000

(Stand: 06/2019)

25

Durchschnittliche Anzahl klinische Studien in der Schweiz pro Jahr

(Stand: 06/2019)

80

Millionen Schweizer Franken in die Forschung investiert, seit 2012

(Stand: 06/2019)

Die klinische Forschung von MSD Schweiz wird in unserer Niederlassung im Citybay in Luzern koordiniert.
Unsere Niederlassungen

Das klinische Studienprogramm von MSD in der Schweiz ist breit gefächert (Stand: 06/2019)

Laufende klinische Studien von MSD in der Schweiz (Stand: 06/2019)

(veröffentlicht auf www.clinicaltrials.gov)

Laufende klinische Studien von MSD in der Schweiz im Bereich Infektiologie (Stand 06/2019)

Studie

Durchführungsort

HIV

MK-1439A-021: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected

Genf, Lausanne, Zürich

MK-1439A-024: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Bern, Lausanne, Zürich

Laufende klinische Studien von MSD in der Schweiz im Bereich Kardiologie (Stand 06/2019)

Studie

Durchführungsort

Herzinsuffizienz

MK-1242-001 (VICTORIA): A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Basel, Lausanne, Lugano

Laufende klinische Studien von MSD in der Schweiz im Bereich Onkologie (Stand 06/2019)

Studie

Durchführungsort

Blasenkrebs

MK-3475-676/KEYNOTE-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Basel, Genf, Zürich

B-Zell-Lymphom

MK-3475-170/KEYNOTE 170: A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)

Bellinzona

Kolorektales Karzinom

MK-3475-177/KEYNOTE-177: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Genf, Zürich

Kopf-und Halskrebs

MK-3475-040/KEYNOTE-040: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Bern, Genf, Luzern

MK-3475-048/KEYNOTE-048: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Basel, Zürich, Lausanne

MK-3475-689/KEYNOTE-689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Bellinzona, Genf, Zürich

Leberkrebs

MK-3475-859/KEYNOTE-937: A phase III adjuvant, randomized, placebo – controlled, double-blinded study, in surgically resected or ablated HCC patients

Basel, Bern, Genf, Lausanne, St.Gallen, Zürich

Lungenkrebs

MK-3475-042/KEYNOTE-042: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Basel, Bern, Freiburg

MK-3475-495/KEYNOTE-495; KeyImPaCT: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

Basel, Chur, Genf, St. Gallen, Zürich

MK-3475-604/KEYNOTE-604: A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Chur, Lausanne, Zürich

MK-3475/KEYNOTE-654-04/ECHO-305-04: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Bern, Genf, Winterthur, Zürich

MK-3475-859/KEYNOTE-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)

Genf, Zürich

Magenkrebs

MK-3475-062/KEYNOTE-062: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Basel, Bern, Chur, Lausanne, Zürich

MK-3475-859/KEYNOTE-859: A Phase III, randomized, double-blind clinical study of pembrolizumab (MK 3475) plus chemotherapy versus placebo plus chemotherapy as first line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma

Basel, Bellinzona, Chur, Genf, Luzern, St.Gallen, Zürich

Melanom

MK-3475-716/KEYNOTE-716: Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Bellinzona, Bern, Chur, Genf, Lausanne, Sion, St. Gallen, Zürich

MK-7902-003: A Phase III, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

Basel, Chur, Lausanne, Zürich

Prostatakrebs

MK-3475-199/KEYNOTE-199: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Basel, Chur, Luzern, St. Gallen

Solide Tumore

MK-3475-587/KEYNOTE-587: Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study

Zürich

MK-7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Bellinzona, Genf, Zürich

MK-8353-014: Phase 1 b Open-label Study of MK-8353 in Combination with Selumetinib (MK-5618) in Participants with Advanced/Metastatic Solid Tumors

Bellinzona

Zur Übersicht der schweizweiten Studien, die Teilnehmende suchen. www.kofam.ch

Wir möchten Menschen mit Krebs Hoffnung schenken

Wir investieren in die Entwicklung innovativer onkologischer Medikamente, um Menschen mit Krebserkrankungen zu helfen.

Mehr erfahren

CH-NON-00136, 06/2019